Clinical Trials Adults with Acute Myelogenous Leukemia: Experience of the Eastern Cooperative Oncology Group
Over the past 15 years, the Eastern Cooperative Oncology Group has conducted a series of studies in patients with AML, sequentially escalating the post-remission therapy. While there has not been a major improvement in the number of adult patients who can achieve a complete remission, intensifying the post remission therapy appears to have led to an improved disease-free survival rate (Fig. 1) and has formed the basis for a major intergroup study prospectively evaluating the role of three different intensive post-remission regimens. This report will focus on de novo AML and, in addition to describing three major ongoing randomized studies, will also discuss the impact that previous ECOG studies have had on the design of current studies for dose intensity in postremission therapy.
KeywordsPlacebo Leukemia Oncol Neutropenia Cyclophosphamide
Unable to display preview. Download preview PDF.
- 2.Mayer RJ (1987) Current chemotherapeutic approaches in the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Hematol 14: 384–397Google Scholar
- 4.Bennett JM, Begg CB (1981) Acute myeloid leukemia by correlation of subtypes with response and survival. Cac Res 41: 4833–4837Google Scholar
- 6.Cassileth PA, McGlave P, Harrington DP et al. (1989) Comparison of post remission therapy in AML: Maintenance versus intensive consolidation therapy versus allogeneic bbne marrow transplantation. Proc ASCO 8: 197Google Scholar
- 7.Cassileth PA, Andersen JW, Bennett JM et al. (1992) Escalating the intensity of post-remission therapy improved the outcome in acute myeloid leukemia: The ECOG experience. Leukemia (in press)Google Scholar